ARGX vs. SMMT: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and SMMT, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ARGX dwarfs SMMT in market cap, clocking in at 35.72 billion USD—about 1.91 times the 18.74 billion USD of its counterpart.
SMMT dances to a riskier tune, sporting a beta of -0.95, while ARGX keeps it calmer at 0.17.
Worth noting: ARGX flies the ADR flag, tying it to a foreign outfit on U.S. soil, while SMMT sticks to plain-vanilla U.S. listing.
| Symbol | ARGX | SMMT |
|---|---|---|
| Company Name | argenx SE | Summit Therapeutics Inc. |
| Country | NL | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. Robert W. Duggan |
| Price | 584.95 USD | 25.41 USD |
| Market Cap | 35.72 billion USD | 18.74 billion USD |
| Beta | 0.17 | -0.948 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 18, 2017 | March 5, 2015 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and SMMT over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ARGX and SMMT based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- SMMT shows a negative P/E of -77.90, highlighting a year of losses with no net profit generated. Meanwhile, ARGX at 51.21 has sustained positive earnings, offering a more stable earnings foundation.
- Both ARGX at -457.12 and SMMT at -108.01 have negative Price-to-Free Cash Flow values. This reveals they’ve been consuming more cash than they generate over the past year—a persistent cash drain that could strain their ability to operate without external funding.
| Symbol | ARGX | SMMT |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 51.21 | -77.90 |
| Forward PEG Ratio (TTM) | 1.36 | 8.05 |
| Price-to-Sales Ratio (P/S, TTM) | 16.54 | 0.00 |
| Price-to-Book Ratio (P/B, TTM) | 7.77 | 54.47 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -457.12 | -108.01 |
| EV-to-EBITDA (TTM) | 4584.81 | -107.59 |
| EV-to-Sales (TTM) | 15.88 | 0.00 |
| EV-to-Free Cash Flow (TTM) | -438.95 | -106.83 |
Dividend Comparison
Neither ARGX nor SMMT pays dividends, suggesting both reinvest all profits into growth—likely expansion or innovation—favoring long-term value over immediate income.
| Symbol | ARGX | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ARGX and SMMT, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ARGX at -20.85 and SMMT at -30.27 both scrape by with interest coverage under 1.5. Earnings are stretched thin against interest bills, leaving little wiggle room if profits drop.
| Symbol | ARGX | SMMT |
|---|---|---|
| Current Ratio (TTM) | 7.29 | 10.63 |
| Quick Ratio (TTM) | 6.68 | 10.63 |
| Debt-to-Equity Ratio (TTM) | 0.01 | 0.02 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.02 |
| Interest Coverage Ratio (TTM) | -20.85 | -30.27 |